Profiling cognitive impairment in treatment-resistant schizophrenia patients

Psychiatry Research

Volumn 235, Issue , 2015, Pages 133-138

  Frydecka, Dorota ^a   Beszłej, Jan Aleksander ^a   Gościmski, Piotr ^b   Kiejna, Andrzej ^a   Misiak, Błazej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Lower Silesian Research Centre   (Poland)

Author keywords

Anticholinergic effect; Antipsychotics; Cognition; Schizophrenia; Treatment resistance

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; PERAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZUCLOPENTHIXOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIGIT SPAN FORWARD AND BACKWARD AND SIMILARITIES; DIGIT SYMBOL CODING TEST; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REY AUDITORY VERBAL LEARNING TEST; SCHIZOPHRENIA; STROOP TEST; THERAPY RESISTANCE; TRAIL MAKING TEST; VERBAL FLUENCY TEST; WECHSLER ADULT INTELLIGENCE SCALE; CHEMICALLY INDUCED; COGNITION; COMPLICATION; DRUG EFFECTS; LEARNING; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGY; WECHSLER INTELLIGENCE SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOPATHOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STROOP TEST; TRAIL MAKING TEST; VERBAL LEARNING; WECHSLER SCALES;

EID: 84954304997     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.11.028     Document Type: Article

References (45)

1. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39(7):784-788.
2. Andreasen N.C. Methods for assessing positive and negative symptoms. Mod. Probl. Pharmacopsychiatry 1990, 24:73-88.
3. Bora E., Yucel M., Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr. Bull. 2010, 36(1):36-42.
4. Bourque J., Lakis N., Champagne J., Stip E., Lalonde P., Lipp O., Mendrek A. Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cogn. Neuropsychiatry 2013, 18(6):615-630.
5. Brissos S., Dias V.V., Balanza-Martinez V., Carita A.I., Figueira M.L. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr. Res. 2011, 129(2-3):133-136.
6. Burns A.M., Erickson D.H., Brenner C.A. Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. Psychiatr. Serv. 2014, 65(7):874-880.
7. Chang W.C., Tang J.Y., Hui C.L., Wong G.H., Chan S.K., Lee E.H., Chen E.Y. The relationship of early premorbid adjustment with negative symptoms and cognitive functions in first-episode schizophrenia: a prospective three-year follow-up study. Psychiatry Res. 2013, 209(3):353-360.
8. Demjaha A., Egerton A., Murray R.M., Kapur S., Howes O.D., Stone J.M., McGuire P.K. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol. Psychiatry 2014, 75(5):e11-e13.
9. Demjaha A., Murray R.M., McGuire P.K., Kapur S., Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am. J. Psychiatry 2012, 169(11):1203-1210.
10. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry 2007, 64(5):532-542.
11. Elkis H. Treatment-resistant schizophrenia. Psychiatr. Clin. North Am. 2007, 30(3):511-533.
12. Ellis J.R., Ellis K.A., Bartholomeusz C.F., Harrison B.J., Wesnes K.A., Erskine F.F., Vitetta L., Nathan P.J. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int. J. Neuropsychopharmacol. 2006, 9(2):175-189.
13. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167(6):686-693.
14. Gold P.E. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol. Learn. Mem. 2003, 80(3):194-210.
15. Gold P.E. Acetylcholine: cognitive and brain functions. Neurobiol. Learn. Mem. 2003, 80(3):177.
16. Gong J., Pinheiro J.C., DeMets D.L. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Control. Clin. Trials 2000, 21(4):313-329.
17. Green A., Ellis K.A., Ellis J., Bartholomeusz C.F., Ilic S., Croft R.J., Phan K.L., Nathan P.J. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol. Biochem. Behav. 2005, 81(3):575-584.
18. Hill S.K., Bishop J.R., Palumbo D., Sweeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expeprt. Rev. Neurother. 2010, 10(1):43-57.
19. Hofer A., Bodner T., Kaufmann A., Kemmler G., Mattarei U., Pfaffenberger N.M., Rettenbacher M.A., Trebo E., Yalcin N., Fleischhacker W.W. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol. Med. 2011, 41(10):2131-2139.
20. Iasevoli F., Balletta R., Gilardi V., Giordano S., de Bartolomeis A. Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatr. Dis. Treat. 2013, 9:1113-1120.
21. Kaneda Y., Jayathilak K., Meltzer H.Y. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. Psychiatry Res. 2009, 169(2):178-179.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
23. Keefe R.S., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33(4):912-920.
24. Kennedy J.L., Altar C.A., Taylor D.L., Degtiar I., Hornberger J.C. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int. Clin. Psychopharmacol. 2014, 29(2):63-76.
25. Koller G., Satzger W., Adam M., Wagner M., Kathmann N., Soyka M., Engel R. Effects of scopolamine on matching to sample paradigm and related tests in human subjects. Neuropsychobiology 2003, 48(2):87-94.
26. Krishnadas R., Jauhar S., Telfer S., Shivashankar S., McCreadie R.G. Nicotine dependence and illness severity in schizophrenia. Br. J. Psychiatry 2012, 201(4):306-312.
27. Kroken R.A., Johnsen E., Ruud T., Wentzel-Larsen T., Jorgensen H.A. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009, 9:24.
28. La Paglia F., La Cascia C., Rizzo R., Sideli L., Francomano A., La Barbera D. Cognitive rehabilitation of schizophrenia through NeuroVr training. Stud. Health Technol. Inf. 2013, 191:158-162.
29. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 2004, 161(2 Suppl):1-56.
30. Mak M., Tybura P., Bienikowski P., Karakiewicz B., Samochowiec J. The efficacy of cognitive neurorehabilitation with RehaCom program in schizophrenia patients. Psychiatr. Pol. 2013, 47(2):213-223.
31. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 1991, 48(8):764-770.
32. McGurk S.R., Green M.F., Wirshing W.C., Wirshing D.A., Marder S.R., Mintz J., Kern R. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr. Res. 2004, 68(2-3):225-233.
33. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 2004, 161(1):116-124.
34. Nakajima S., Takeuchi H., Plitman E., Fervaha G., Gerretsen P., Caravaggio F., Chung J.K., Iwata Y., Remington G., Graff-Guerrero A. Neuroimaging findings in treatment-resistant schizophrenia: a systematic review: lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr. Res. 2015, 164(1-3):164-175.
35. Ogino S., Miyamoto S., Miyake N., Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin. Neurosci. 2014, 68(1):37-49.
36. Sadock B., Sadock V., Sussman N. Kaplan and Sadock's Pocket Handbook of Psychiatric Drug Treatment 2006, Lippincott Williams & Wilkins, Baltimore, MD.
37. Strauss M.E., Reynolds K.S., Jayaram G., Tune L.E. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 1990, 3(2):127-129.
38. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J. Clin. Psychiatry 2011, 72(Suppl. 1):S4-S8.
39. Terry A.V., Mahadik S.P. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J. Pharmacol. Exp. Ther. 2007, 320(3):961-968.
40. Tybura P., Mak M., Samochowiec A., Pelka-Wysiecka J., Grzywacz A., Grochans E., Zaremba-Pechmann L., Samochowiec J. The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients. Psychiatr. Pol. 2013, 47(4):567-578.
41. Vinogradov S., Fisher M., Warm H., Holland C., Kirshner M.A., Pollock B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 2009, 166(9):1055-1062.
42. Wing V.C., Wass C.E., Soh D.W., George T.P. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann. NY Acad. Sci. 2012, 1248:89-106.
43. Zhang X.Y., Chen D.C., Xiu M.H., Haile C.N., He S.C., Luo X., Zuo L., Rosenheck R., Kosten T.A., Kosten T.R. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. Psychol. Med. 2013, 43(8):1651-1660.
44. Zugman A., Gadelha A., Assuncao I., Sato J., Ota V.K., Rocha D.L., Mari J.J., Belangero S.I., Bressan R.A., Brietzke E., Jackowski A.P. Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. Schizophr. Res. 2013, 148(1-3):81-86.
45. de Bartolomeis A., Balletta R., Giordano S., Buonaguro E.F., Latte G., Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013, 210(2):387-395.